310 related articles for article (PubMed ID: 15574781)
1. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Zhang M; Mukherjee N; Bermudez RS; Latham DE; Delaney MA; Zietman AL; Shipley WU; Chakravarti A
Prostate; 2005 Aug; 64(3):293-302. PubMed ID: 15754318
[TBL] [Abstract][Full Text] [Related]
4. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
Li J; Liu P; Mao H; Wanga A; Zhang X
Oncol Rep; 2009 Jun; 21(6):1605-10. PubMed ID: 19424643
[TBL] [Abstract][Full Text] [Related]
5. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
7. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells.
Pratt MA; Niu MY; Renart LI
Apoptosis; 2006 Apr; 11(4):589-605. PubMed ID: 16528475
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
9. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
10. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.
Wall NR; O'Connor DS; Plescia J; Pommier Y; Altieri DC
Cancer Res; 2003 Jan; 63(1):230-5. PubMed ID: 12517802
[TBL] [Abstract][Full Text] [Related]
11. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
12. Activation of p34cdc2 coincident with taxol-induced apoptosis.
Donaldson KL; Goolsby GL; Kiener PA; Wahl AF
Cell Growth Differ; 1994 Oct; 5(10):1041-50. PubMed ID: 7848905
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.
Dan HC; Jiang K; Coppola D; Hamilton A; Nicosia SV; Sebti SM; Cheng JQ
Oncogene; 2004 Jan; 23(3):706-15. PubMed ID: 14737105
[TBL] [Abstract][Full Text] [Related]
14. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
Mita AC; Mita MM; Nawrocki ST; Giles FJ
Clin Cancer Res; 2008 Aug; 14(16):5000-5. PubMed ID: 18698017
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.
Tirrò E; Consoli ML; Massimino M; Manzella L; Frasca F; Sciacca L; Vicari L; Stassi G; Messina L; Messina A; Vigneri P
Cancer Res; 2006 Apr; 66(8):4263-72. PubMed ID: 16618750
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
17. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
18. Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
Chen JG; Yang CP; Cammer M; Horwitz SB
Cancer Res; 2003 Nov; 63(22):7891-9. PubMed ID: 14633718
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
20. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
